LXEO vs RCKT
LXEO: Lexeo Therapeutics is a clinical-stage genetic medicine company developing pioneering gene therapies for cardiovascular diseases with high unmet needs. RCKT: Rocket Pharmaceuticals is a commercial-stage biotech company developing AAV-based gene therapies for rare cardiovascular conditions and genetic disorders.
Side-by-side fundamentals
| Metric | LXEO | RCKT | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $3.00 | $2.20 | |
| Market cap | $246M | $242M | |
| Net margin FY2022, SEC XBRL | -9063.8% | n/a | |
| Operating margin FY2022, SEC XBRL | -9252.1% | n/a | |
| ROE FY2025, SEC XBRL | -40.5% | -80.5% | LXEO higher |
| ROA FY2025, SEC XBRL | -37.2% | -67.5% | LXEO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.01 | 1.59 | |
| 1-year return as of 2026-10-21 close | -68.8% | -44.7% | RCKT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.